Privia Health Group (PRVA) Q3 2024 earnings summary

Executive summary

• Achieved strong financial and operational performance in Q3 2024, with implemented providers up 13.1% to 4,642 and attributed lives up 14% to 1.25 million year-over-year.

• Expanded into Indiana with a new multi-specialty practice, now operating in 14 states and D.C., and record new provider signings year-to-date.

• Maintained high provider retention (98%) and patient satisfaction (Net Promoter Score of 85), serving over 5.1 million patients.

• Delivered $176.6 million in MSSP 2023 shared savings, up 34.1% year-over-year, with $117.4 million recognized as revenue.

• Net income for Q3 2024 was $3.5 million, down from $5.6 million in Q3 2023, primarily due to higher operating expenses and stock-based compensation.

Financial highlights

• Q3 2024 revenue was $437.9 million, up 4.9% year-over-year; practice collections reached $739.9 million, up 2.3% year-over-year.

• Adjusted EBITDA for Q3 2024 was $23.6 million (23.3% margin), up 25.8% year-over-year; care margin was $101.4 million, up 10.2% year-over-year.

• Free cash flow year-to-date was $87 million, with a pro forma cash balance of $473.5 million and no debt.

• Adjusted net income per diluted share for Q3 2024 was $0.20, up from $0.17 in Q3 2023.

• Cash and cash equivalents at September 30, 2024, were $422.0 million.

Outlook and guidance

• Raised 2024 guidance to the high end or above for all metrics, including implemented providers (4,750), attributed lives (above 1.2 million), practice collections ($2.875 billion), GAAP revenue ($1.675 billion), care margin ($400 million), and adjusted EBITDA ($90 million).

• Targeting annual adjusted EBITDA growth of 20% or greater, with about 90% of full-year adjusted EBITDA expected to convert to free cash flow.

• Management expects continued revenue and margin growth through provider and patient additions, new market entries, and expansion of value-based care arrangements.